Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.17 USD
Change Today +0.08 / 1.31%
Volume 9.1K
HSGX On Other Exchanges
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

histogenics corp (HSGX) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/3/14 - $12.97
52 Week Low
08/24/15 - $5.09
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for HISTOGENICS CORP (HSGX)

Related News

No related news articles were found.

histogenics corp (HSGX) Related Businessweek News

No Related Businessweek News Found

histogenics corp (HSGX) Details

Histogenics Corporation develops and commercializes regenerative medicine products in the musculoskeletal segment of the marketplace. Its product candidate includes NeoCart, which is in Phase III clinical trials, a first-line therapy for full thickness knee chondral lesions in skeletally mature adults age 18 to 55. The company has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was incorporated in 2000 and is headquartered in Waltham, Massachusetts.

42 Employees
Last Reported Date: 03/27/15
Founded in 2000

histogenics corp (HSGX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $224.3K
Chief Technology Officer
Total Annual Compensation: $309.2K
Compensation as of Fiscal Year 2014.

histogenics corp (HSGX) Key Developments

Histogenics Corporation Reports Earnings Results for the Second Quarter of 2015

Histogenics Corporation reported earnings results for the second quarter of 2015. For the quarter, net loss was $7.6 million, or $0.58 per share compared to $11.8 million, or $19.85 per share in second quarter of 2014. The company reported no revenues for the quarter.

Histogenics Corporation Announces Appointment of Stephen Kennedy to Chief Technology Officer

Histogenics Corporation announced the promotion of Stephen Kennedy to Chief Technology Officer, effective immediately. Mr. Kennedy brings more than 30 years of executive product development, manufacturing, technology assessment and commercialization experience at leading biotechnology companies and esteemed academic institutions, including Genzyme, MIT, and Genencor. He has substantial experience taking early-stage technologies through development, approval and commercial launch using a variety of U.S. and global regulatory pathways, including biologics, drugs and medical devices, and will oversee all manufacturing, research & development, technology assessment, intellectual property and collaboration activities with advisory board and collaboration partners. Prior to joining Histogenics in 2013 as Senior Vice President of Technical Operations, Mr. Kennedy served as the Executive Vice President, Research and Development, at Mascoma Corporation, a biofuel company from 2011 to 2013.

Histogenics Corporation, Q2 2015 Earnings Call, Aug 12, 2015

Histogenics Corporation, Q2 2015 Earnings Call, Aug 12, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HSGX:US $6.17 USD +0.08

HSGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HSGX.
View Industry Companies

Industry Analysis


Industry Average

Valuation HSGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HISTOGENICS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at